^
Association details:
| Biomarker: | ALK F1245C |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
A novel acquired ALK F1245C mutation confers resistance to crizotinib in ALK-positive NSCLC but is sensitive to ceritinib
Excerpt:
Here we described the emergence of an ALK F1245C mutation in an advanced ALK+ NSCLC patient (EML4-ALK variant 3a/b) who developed slow disease progression after a durable response to crizotinib….This is the first patient report that ALK F1245C is an acquired resistance mutation to crizotinib...
DOI:
10.1016/j.lungcan.2015.11.023
